Cardioprotective Effects of Losartan and Diminazene against the Ischemia/Reperfusion Injury in Hyperthyroidism Rats

Can J Physiol Pharmacol. 2024 Feb 20. doi: 10.1139/cjpp-2023-0122. Online ahead of print.ABSTRACTHyperthyroidism is a condition where the thyroid gland produces high levels of thyroid hormone. Heart diseases are one of the main complications of hyperthyroidism. Several studies have shown that losartan (LOS) and diminazene aceturate (DIZE) possess cardioprotection effects against cardiac hypertrophy, ischemic heart disease, and heart failure. The research aimed to investigate the cardioprotection of LOS, DIZE, and their combination in the case of levothyroxine-induced cardiomyopathy in rats. Hyperthyroidism was induced by levothyroxine (LT4) in drinking water (12 mg/L) for 28 days. LOS (10 mg/kg, orally) and/or DIZE (15 mg/kg, subcutaneously) were administrated in rats with hyperthyroidism for 28 days. Decreased serum CK-MB and LDH levels and cardiac hypertrophy by DIZE and combination therapy in hyperthyroidism rats have been reported. Cardiac hemodynamic findings showed that DIZE and its combination with LOS decreased the LT4-mediated LVDP, RPP, and RPP recovery percentage. Elevated cardiac oxidative stress and inflammation were confirmed by decreasing cardiac SOD activity and increasing the TOS and TNF-α levels. SOD activity, and TNF-α level were reversed by LOS and DIZE administration respectively. Generally, DIZE and combination therapy with LOS improved cardiac dysfunction caused by hyperthyroidism in rats, whereas, LOS alone has not been able to effectively respond to...
Source: Canadian Journal of Physiology and Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research